MicroRNAs in islet immunobiology and transplantation

Immunologic Research

Volumn 57, Issue 1-3, 2013, Pages 185-196

  Pileggi, Antonello ^a,b,c   Klein, Dagmar ^a   Fotino, Carmen ^a   Bravo Egaña, Valia ^a   Rosero, Samuel ^a   Doni, Marco ^a,d,e   Podetta, Michele ^a,d,e   Ricordi, Camillo ^a,b,c   Molano, R Damaris ^a   Pastori, Ricardo L ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c University of Miami College of Engineering   (United States)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Autoimmunity; Bioengineering; Bioinformatics; Biomarker; Cell transplantation; Cellular therapies; Diabetes; Diabetes mellitus; Engraftment; Implantable device; Inflammation; Innate immunity; Islet transplantation; MicroRNA; Molecular target; Neovascularization; Rejection; Tissue engineering; Transplant microenvironment; Type 1 diabetes

Indexed keywords

MICRORNA;

ARTICLE; GENE EXPRESSION; HUMAN; IMMUNOBIOLOGY; IMMUNOMODULATION; PANCREAS ISLET; PANCREAS ISLET DISEASE; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RNA TRANSLATION;

ANIMALS; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HUMANS; INFLAMMATION; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICRORNAS; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 84891483568     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-013-8436-5     Document Type: Article

References (132)

1. Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, Kantz J, et al. Pancreatic islet production of vascular endothelial growth factor - a is essential for islet vascularization, revascularization, and function. Diabetes. 2006;55(11):2974-85. doi: 10.2337/db06-0690.
2. Toyofuku Y, Uchida T, Nakayama S, Hirose T, Kawamori R, Fujitani Y, et al. Normal islet vascularization is dispensable for expansion of beta-cell mass in response to high-fat diet induced insulin resistance. Biochem Biophys Res Commun. 2009;383(3):303-7. doi: 10.1016/j.bbrc.2009.03.138.
3. Gu Y, Zhang M, Chen H, Wang Z, Xing C, Yang H, et al. Discordant association of islet autoantibodies with high-risk HLA genes in Chinese type 1 diabetes. Diabetes Metab Res Rev. 2011;27(8):899-905. doi: 10.1002/dmrr.1270.
4. Abreu JR, Roep BO. Immune monitoring of islet and pancreas transplant recipients. Curr Diab Rep. 2013;13(5):704-12. doi: 10.1007/s11892-013-0399-3.
5. Mineo D, Pileggi A, Alejandro R, Ricordi C. Point: steady progress and current challenges in clinical islet transplantation. Diabetes Care. 2009;32(8):1563-9. doi: 10.2337/dc09-0490.
6. Piemonti L, Pileggi A. 25 years of the Ricordi automated method for islet isolation. CellR4. 2013;1(1):8-22.
7. Pileggi A. Islet transplantation. Entotext.org. South Dartmouth, MA: MDText.com, Inc; 2011.
8. Pileggi A, Ricordi C. A new home for pancreatic islet transplants: the bone marrow. Diabetes. 2013;62(10):3333-5. doi: 10.2337/db13-1039.
9. Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes. 2010;59(4):947-57. doi: 10.2337/db09-0498.
10. Burke GW III, Vendrame F, Pileggi A, Ciancio G, Reijonen H, Pugliese A. Recurrence of autoimmunity following pancreas transplantation. Curr Diab Rep. 2011;11(5):413-9. doi: 10.1007/s11892-011-0206-y.
11. Ambros V. MicroRNAs: tiny regulators with great potential. Cell. 2001;107(7):823-6.
12. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-97.
13. Pasquinelli AE. MicroRNAs: deviants no longer. Trends Genet. 2002;18(4):171-3.
14. Griffiths-Jones S the microRNA registry. Nucl Acids Res. 2004;32(Database issue):D109-11.
15. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucl Acids Res. 2006;34(Database issue):D140-4.
16. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20.
17. Rajewsky N. MicroRNA target predictions in animals. Nat Genet. 2006;38(Suppl):S8-13.
18. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15(2):185-97.
19. Hutvagner G, McLachlan J, Pasquinelli AE, Balint E, Tuschl T, Zamore PD. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293(5531):834-8.
20. Petersen CP, Bordeleau ME, Pelletier J, Sharp PA. Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 2006;21(4):533-42.
21. Wu L, Fan J, Belasco JG. MicroRNAs direct rapid deadenylation of mRNA. Proc Natl Acad Sci USA. 2006;103(11):4034-9.
22. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11(4):252-63.
23. Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I, et al. TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol. 2009;11(7):881-9.
24. Cui Q, Yu Z, Purisima EO, Wang E. Principles of microRNA regulation of a human cellular signaling network. Mol Syst Biol. 2006;2:46.
25. Grimson A, Farh KK, Johnston WK, Garrett-Engele P, Lim LP, Bartel DP. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell. 2007;27(1):91-105.
26. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769-73.
27. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih IM, Zhang Y, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One. 2008;3(6):e2436.
28. Nicolas FE, Pais H, Schwach F, Lindow M, Kauppinen S, Moulton V, et al. Experimental identification of microRNA-140 targets by silencing and overexpressing miR-140. RNA. 2008;14(12):2513-20.
29. Wang X. Systematic identification of microRNA functions by combining target prediction and expression profiling. Nucl Acids Res. 2006;34(5):1646-52.
30. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835-40. doi: 10.1038/nature09267.
31. Guimbellot JS, Erickson SW, Mehta T, Wen H, Page GP, Sorscher EJ, et al. Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics. 2009;2:15.
32. Wang L, Oberg AL, Asmann YW, Sicotte H, McDonnell SK, Riska SM, et al. Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. PLoS One. 2009;4(6):e5878.
33. Wang YP, Li KB. Correlation of expression profiles between microRNAs and mRNA targets using NCI-60 data. BMC Genomics. 2009;10:218.
34. Nakasa T, Miyaki S, Okubo A, Hashimoto M, Nishida K, Ochi M, et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 2008;58(5):1284-92.
35. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 2007;104(5):1604-9.
36. Sonkoly E, Stahle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol. 2008;18(2):131-40.
37. Urbich C, Kuehbacher A, Dimmeler S. Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 2008;79(4):581-8.
38. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl Res. 2011;157(4):253-64. doi: 10.1016/j.trsl.2011.01.009.
39. Herrera BM, Lockstone HE, Taylor JM, Ria M, Barrett A, Collins S, et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia. 2010;53(6):1099-109. doi: 10.1007/s00125-010-1667-2.
40. Tang X, Tang G, Ozcan S. Role of microRNAs in diabetes. Biochim Biophys Acta. 2008;1779(11):697-701. doi: 10.1016/j.bbagrm.2008.06.010.
41. Esguerra JL, Bolmeson C, Cilio CM, Eliasson L. Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model goto-Kakizaki rat. PLoS One. 2011;6(4):e18613. doi: 10.1371/journal.pone.0018613.
42. Roggli E, Britan A, Gattesco S, Lin-Marq N, Abderrahmani A, Meda P, et al. Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes. 2010;59(4):978-86. doi: 10.2337/db09-0881.
43. Bravo-Egana V, Rosero S, Molano RD, Pileggi A, Ricordi C, Dominguez-Bendala J, et al. Quantitative differential expression analysis reveals miR-7 as major islet microRNA. Biochem Biophys Res Commun. 2008;366(4):922-6. doi: 10.1016/j.bbrc.2007.12.052.
44. Klein D, Misawa R, Bravo-Egana V, Vargas N, Rosero S, Piroso J, et al. MicroRNA expression in alpha and beta cells of human pancreatic islets. PLoS One. 2013;8(1):e55064. doi: 10.1371/journal.pone.0055064.
45. Bravo V, Rosero S, Ricordi C, Pastori RL. Instability of miRNA and cDNAs derivatives in RNA preparations. Biochem Biophys Res Commun. 2007;353(4):1052-5. doi: 10.1016/j.bbrc.2006.12.135.
46. Correa-Medina M, Bravo-Egana V, Rosero S, Ricordi C, Edlund H, Diez J, et al. MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas. Gene Expr Patterns. 2009;9(4):193-9. doi: 10.1016/j.gep.2008.12.003.
47. Rosero S, Bravo-Egana V, Jiang Z, Khuri S, Tsinoremas N, Klein D, et al. MicroRNA signature of the human developing pancreas. BMC Genomics. 2010;11:509. doi: 10.1186/1471-2164-11-509.
48. Dominguez-Bendala J, Klein D, Pastori RL. MicroRNA-7 control of beta-cell replication. Diabetes. 2013;62(3):694-5. doi: 10.2337/db12-1518.
49. Nieto M, Hevia P, Garcia E, Klein D, Alvarez-Cubela S, Bravo-Egana V, et al. Antisense miR-7 impairs insulin expression in developing pancreas and in cultured pancreatic buds. Cell Transpl. 2012;21(8):1761-74. doi: 10.3727/096368911X612521.
50. Dominguez-Bendala J, Alvarez-Cubela S, Nieto M, Vargas N, Espino-Grosso P, Sacher VY, et al. Intracardial embryonic delivery of developmental modifiers in utero. Cold Spring Harbor Protoc. 2012;2012(9):962-8. doi: 10.1101/pdb.prot069427.
51. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;108(12):5003-8. doi: 10.1073/pnas.1019055108.
52. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9(6):654-9. doi: 10.1038/ncb1596.
53. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010;107(6):810-7. doi: 10.1161/CIRCRESAHA.110.226357.
54. Eizirik DL, Colli ML, Ortis F the role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5(4):219-26. doi: 10.1038/nrendo.2009.21.
55. Baker MS, Chen X, Rotramel A, Nelson J, Kaufman DB. Proinflammatory cytokines induce NF-kappaB-dependent/NO-independent chemokine gene expression in MIN6 beta cells. J Surg Res. 2003;110(1):295-303.
56. Baquerizo H, Rabinovitch A. Interferon-gamma sensitizes rat pancreatic islet cells to lysis by cytokines and cytotoxic cells. J Autoimmun. 1990;3(Suppl 1):123-30.
57. Hohmeier HE, Tran VV, Chen G, Gasa R, Newgard CB. Inflammatory mechanisms in diabetes: lessons from the beta-cell. Int J Obes Relat Metab Disord. 2003;27(Suppl 3):S12-6.
58. Sandler S, Eizirik DL, Sternesjo J, Welsh N. Role of cytokines in regulation of pancreatic B-cell function. Biochem Soc Trans. 1994;22(1):26-30.
59. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H, Perren A, Ehses JA. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care. 2008;31(Suppl 2):S161-4.
60. Nolan CJ, Madiraju MS, Delghingaro-Augusto V, Peyot ML, Prentki M. Fatty acid signaling in the beta-cell and insulin secretion. Diabetes. 2006;55(Suppl 2):S16-23.
61. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2008;29(3):351-66.
62. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358(9277):221-9.
63. Mathis D, Vence L, Benoist C. Beta-cell death during progression to diabetes. Nature. 2001;414(6865):792-8.
64. Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, Degauque N, et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci USA. 2007;104(32):13074-9.
65. Pileggi A, Molano RD, Berney T, Cattan P, Vizzardelli C, Oliver R, et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes. 2001;50(9):1983-91.
66. Pileggi A, Molano RD, Berney T, Ichii H, San Jose S, Zahr E, et al. Prolonged allogeneic islet graft survival by protoporphyrins. Cell Transpl. 2005;14(2-3):85-96.
67. Bravo-Egana V, Rosero S, Klein D, Jiang Z, Vargas N, Tsinoremas N, et al. Inflammation-mediated regulation of microRNA expression in transplanted pancreatic islets. J Transpl. 2012;2012:723614. doi: 10.1155/2012/723614.
68. Bendtzen K, Mandrup-Poulsen T, Nerup J, Nielsen JH, Dinarello CA, Svenson M. Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science. 1986;232(4757):1545-7.
69. Eizirik DL, Sandler S, Welsh N, Cetkovic-Cvrlje M, Nieman A, Geller DA, et al. Cytokines suppress human islet function irrespective of their effects on nitric oxide generation. J Clin Invest. 1994;93(5):1968-74.
70. Castoldi M, Schmidt S, Benes V, Noerholm M, Kulozik AE, Hentze MW, et al. A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA). RNA. 2006;12(5):913-20. doi: 10.1261/rna.2332406.
71. Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, Kruhoffer M, et al. A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic beta-cells. J Biol Chem. 2001;276(52):48879-86. doi: 10.1074/jbc.M108658200.
72. Laybutt DR, Kaneto H, Hasenkamp W, Grey S, Jonas JC, Sgroi DC, et al. Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to beta-cell survival during chronic hyperglycemia. Diabetes. 2002;51(2):413-23.
73. Ortis F, Pirot P, Naamane N, Kreins AY, Rasschaert J, Moore F, et al. Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia. 2008;51(7):1213-25. doi: 10.1007/s00125-008-0999-7.
74. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-{kappa}B signaling. J Mol Cell Biol. 2011;. doi: 10.1093/jmcb/mjr007.
75. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272(34):21096-103.
76. Laybutt DR, Hawkins YC, Lock J, Lebet J, Sharma A, Bonner-Weir S, et al. Influence of diabetes on the loss of beta cell differentiation after islet transplantation in rats. Diabetologia. 2007;50(10):2117-25.
77. Sarkar SA, Kutlu B, Velmurugan K, Kizaka-Kondoh S, Lee CE, Wong R, et al. Cytokine-mediated induction of anti-apoptotic genes that are linked to nuclear factor kappa-B (NF-kappaB) signalling in human islets and in a mouse beta cell line. Diabetologia. 2009;52(6):1092-101. doi: 10.1007/s00125-009-1331-x.
78. Ortis F, Naamane N, Flamez D, Ladriere L, Moore F, Cunha DA, et al. Cytokines interleukin-1beta and tumor necrosis factor-alpha regulate different transcriptional and alternative splicing networks in primary beta-cells. Diabetes. 2010;59(2):358-74. doi: 10.2337/db09-1159.
79. Fujimoto K, Shibasaki T, Yokoi N, Kashima Y, Matsumoto M, Sasaki T, et al. Piccolo, a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII.Rim2. Piccolo complex in cAMP-dependent exocytosis. J Biol Chem. 2002;277(52):50497-502. doi: 10.1074/jbc.M210146200.
80. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O'Leary JJ, Ruan Q, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol. 2010;11(2):141-7. doi: 10.1038/ni.1828.
81. Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS, Matschinsky F, et al the microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci USA. 2011;108(29):12030-5. doi: 10.1073/pnas.1101450108.
82. Nyqvist D, Kohler M, Wahlstedt H, Berggren PO. Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. Diabetes. 2005;54(8):2287-93.
83. Moritz W, Meier F, Stroka DM, Giuliani M, Kugelmeier P, Nett PC, et al. Apoptosis in hypoxic human pancreatic islets correlates with HIF-1alpha expression. FASEB J. 2002;16(7):745-7.
84. Vasir B, Jonas JC, Steil GM, Hollister-Lock J, Hasenkamp W, Sharma A, et al. Gene expression of VEGF and its receptors Flk-1/KDR and Flt-1 in cultured and transplanted rat islets. Transplantation. 2001;71(7):924-35.
85. Pileggi A, Ribeiro MM, Hogan AR, Molano RD, Cobianchi L, Ichii H, et al. Impact of pancreatic cold preservation on rat islet recovery and function. Transplantation. 2009;87(10):1442-50.
86. Miao G, Ostrowski RP, Mace J, Hough J, Hopper A, Peverini R, et al. Dynamic production of hypoxia-inducible factor-1alpha in early transplanted islets. Am J Transpl. 2006;6(11):2636-43.
87. Mattsson G, Jansson L, Carlsson PO. Decreased vascular density in mouse pancreatic islets after transplantation. Diabetes. 2002;51(5):1362-6.
88. Brissova M, Fowler M, Wiebe P, Shostak A, Shiota M, Radhika A, et al. Intraislet endothelial cells contribute to revascularization of transplanted pancreatic islets. Diabetes. 2004;53(5):1318-25.
89. Pileggi A, Molano RD, Ricordi C, Zahr E, Collins J, Valdes R, et al. Reversal of diabetes by pancreatic islet transplantation into a subcutaneous, neovascularized device. Transplantation. 2006;81(9):1318-24. doi: 10.1097/01.tp.0000203858.41105.88.
90. Bocca N, Pileggi A, Molano RD, Marzorati S, Wu W, Bodor N, et al. Soft corticosteroids for local immunosuppression: exploring the possibility for the use of loteprednol etabonate for islet transplantation. Pharmazie. 2008;63(3):226-32.
91. Marzorati S, Bocca N, Molano RD, Hogan AR, Doni M, Cobianchi L, et al. Effects of systemic immunosuppression on islet engraftment and function into a subcutaneous biocompatible device. Transpl Proc. 2009;41(1):352-3. doi: 10.1016/j.transproceed.2008.09.057.
92. Buchwald P, Bocca N, Marzorati S, Hochhaus G, Bodor N, Stabler C, et al. Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation. Pharmazie. 2010;65(6):421-8.
93. Cantarelli E, Piemonti L. Alternative transplantation sites for pancreatic islet grafts. Curr Diab Rep. 2011;11(5):364-74. doi: 10.1007/s11892-011-0216-9.
94. Watada H. Role of VEGF-A in pancreatic beta cells. Endocr J. 2010;57(3):185-91.
95. Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, et al. Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes. 2004;53(4):963-70.
96. Golocheikine A, Tiriveedhi V, Angaswamy N, Benshoff N, Sabarinathan R, Mohanakumar T. Cooperative signaling for angiogenesis and neovascularization by VEGF and HGF following islet transplantation. Transplantation. 2010;90(7):725-31.
97. Chow LW, Wang LJ, Kaufman DB, Stupp SI. Self-assembling nanostructures to deliver angiogenic factors to pancreatic islets. Biomaterials. 2010;31(24):6154-61.
98. Shimoda M, Chen S, Noguchi H, Matsumoto S, Grayburn PA. In vivo non-viral gene delivery of human vascular endothelial growth factor improves revascularisation and restoration of euglycaemia after human islet transplantation into mouse liver. Diabetologia. 2010;53(8):1669-79.
99. Cabric S, Sanchez J, Johansson U, Larsson R, Nilsson B, Korsgren O, et al. Anchoring of vascular endothelial growth factor to surface-immobilized heparin on pancreatic islets: implications for stimulating islet angiogenesis. Tissue Eng Part A. 2010;16(3):961-70.
100. Ehrbar M, Metters A, Zammaretti P, Hubbell JA, Zisch AH. Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. J Control Release. 2005;101(1-3):93-109.
101. Ehrbar M, Zeisberger SM, Raeber GP, Hubbell JA, Schnell C, Zisch AH the role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. Biomaterials. 2008;29(11):1720-9.
102. Yang WJ, Yang DD, Na S, Sandusky GE, Zhang Q, Zhao G. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem. 2005;280(10):9330-5.
103. Suarez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res. 2009;104(4):442-54.
104. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets. 2010;11(8):943-9.
105. Kuehbacher A, Urbich C, Dimmeler S. Targeting microRNA expression to regulate angiogenesis. Trends Pharmacol Sci. 2008;29(1):12-5.
106. Ferrara N, Gerber HP, LeCouter J the biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76.
107. Finnerty JR, Wang WX, Hebert SS, Wilfred BR, Mao G, Nelson PT the miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol. 2010;402(3):491-509.
108. Kulshreshtha R, Davuluri RV, Calin GA, Ivan M. A microRNA component of the hypoxic response. Cell Death Differ. 2008;15(4):667-71.
109. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003;9(6):677-84.
110. Hua Z, Lv Q, Ye W, Wong CK, Cai G, Gu D, et al. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS One. 2006;1:e116.
111. Kuehbacher A, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. Circ Res. 2007;101(1):59-68.
112. Nicoli S, Standley C, Walker P, Hurlstone A, Fogarty KE, Lawson ND. MicroRNA-mediated integration of haemodynamics and VEGF signalling during angiogenesis. Nature. 2010;464(7292):1196-200.
113. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, Hill JA, et al the endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell. 2008;15(2):261-71.
114. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2):272-84.
115. Carlsson PO, Mattsson G. Oxygen tension and blood flow in relation to revascularization in transplanted adult and fetal rat pancreatic islets. Cell Transpl. 2002;11(8):813-20.
116. Morini S, Brown ML, Cicalese L, Elias G, Carotti S, Gaudio E, et al. Revascularization and remodelling of pancreatic islets grafted under the kidney capsule. J Anat. 2007;210(5):565-77. doi: 10.1111/j.1469-7580.2007.00717.x.
117. Speier S, Nyqvist D, Cabrera O, Yu J, Molano RD, Pileggi A, et al. Noninvasive in vivo imaging of pancreatic islet cell biology. Nat Med. 2008;14(5):574-8. doi: 10.1038/nm1701.
118. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-8.
119. Kloosterman WP, Lagendijk AK, Ketting RF, Moulton JD, Plasterk RH. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol. 2007;5(8):e203.
120. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucl Acids Res. 2005;33(4):1290-7.
121. Le MT, Teh C, Shyh-Chang N, Xie H, Zhou B, Korzh V, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23(7):862-76.
122. Walker JC, Harland RM. MicroRNA-24a is required to repress apoptosis in the developing neural retina. Genes Dev. 2009;23(9):1046-51.
123. Choi WY, Giraldez AJ, Schier AF. Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science. 2007;318(5848):271-4.
124. Weiss FU, Marques IJ, Woltering JM, Vlecken DH, Aghdassi A, Partecke LI, et al. Retinoic acid receptor (RAR) antagonists inhibit miR-10a expression and block metastatic behaviour of pancreatic cancer. Gastroenterology. 2009;137(6):2136-45.
125. Kuhnert F, Mancuso MR, Hampton J, Stankunas K, Asano T, Chen CZ, et al. Attribution of vascular phenotypes of the murine Egfl7 locus to the microRNA miR-126. Development. 2008;135(24):3989-93.
126. Kuhnert F, Kuo CJ. miR-17-92 angiogenesis micromanagement. Blood. 2010;115(23):4631-3.
127. Fang L, Deng Z, Shatseva T, Yang J, Peng C, Du WW, et al. MicroRNA miR-93 promotes tumor growth and angiogenesis by targeting integrin-beta8. Oncogene. 2011;30(7):806-21.
128. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood. 2008;111(3):1217-26.
129. Chan LS, Yue PY, Mak NK, Wong RN. Role of microRNA-214 in ginsenoside-Rg1-induced angiogenesis. Eur J Pharm Sci. 2009;38(4):370-7.
130. Wurdinger T, Tannous BA, Saydam O, Skog J, Grau S, Soutschek J, et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 2008;14(5):382-93.
131. Poliseno L, Tuccoli A, Mariani L, Evangelista M, Citti L, Woods K, et al. MicroRNAs modulate the angiogenic properties of HUVECs. Blood. 2006;108(9):3068-71.
132. Ghosh G, Subramanian IV, Adhikari N, Zhang X, Joshi HP, Basi D, et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-alpha isoforms and promotes angiogenesis. J Clin Invest. 2010;120(11):4141-54.